Anti-DKK3 monoclonal antibody(Stellanova Therapeutics)

N/A

Report date: 2023/01/09 16:01:39

Base Information

Drug NameAnti-DKK3 monoclonal antibody(Stellanova Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionImmunomodulatorsT lymphocytes stimulantsDickkopf-related protein 3 stimulants
TargetsDickkopf-related protein 3
Therapy Area/IndicationsPancreatic NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStellanova Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesStellanova Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A